Oneness Biotech (TPEX:4743) - Aktienkurs, Nachrichten und Analyse

4743 Aktienübersicht

Engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan.

4743 grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	1/6
Künftiges Wachstum	1/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

Revenue is forecast to grow 18.93% per year

Risikoanalyse

Does not have meaningful revenue (NT$102M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Oneness Biotech Co., Ltd. Wettbewerber

Caliway Biopharmaceuticals

TPEX:6919

NT$82.0b

Lotus Pharmaceutical

TWSE:1795

NT$69.7b

Bora Pharmaceuticals

TWSE:6472

NT$75.6b

Lumosa Therapeutics

TPEX:6535

NT$54.6b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Oneness Biotech
Historische Aktienkurse
Aktueller Aktienkurs	NT$143.00
52-Wochen-Hoch	NT$241.44
52-Wochen-Tief	NT$128.00
Beta	1.59
11 Monat Veränderung	-11.73%
3 Monate Veränderung	-5.57%
1 Jahr Veränderung	-14.93%
33 Jahre Veränderung	-3.49%
5 Jahre Veränderung	512.29%
Veränderung seit IPO	1,027.89%

Aktuelle Nachrichten und Updates

Recent updates

Announcing: Oneness Biotech (GTSM:4743) Stock Soared An Exciting 936% In The Last Three Years

Mar 01

Aktionärsrenditen

	4743	TW Pharmaceuticals	TW Markt
7D	1.1%	2.7%	2.8%
1Y	-14.9%	15.4%	37.9%

Rendite im Vergleich zur Industrie: 4743 underperformed the TW Pharmaceuticals industry which returned 15.4% over the past year.

Rendite vs. Markt: 4743 underperformed the TW Market which returned 37.9% over the past year.

Preisvolatilität

Is 4743's price volatile compared to industry and market?
4743 volatility
4743 Average Weekly Movement	7.0%
Pharmaceuticals Industry Average Movement	5.0%
Market Average Movement	5.8%
10% most volatile stocks in TW Market	9.4%
10% least volatile stocks in TW Market	3.1%

Stabiler Aktienkurs: 4743 has not had significant price volatility in the past 3 months.

Volatilität im Zeitverlauf: 4743's weekly volatility (7%) has been stable over the past year.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2008	n/a	Shuling Cheng	www.onenessbio.com

Oneness Biotech Co., Ltd.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Oneness Biotech im Vergleich zum Marktanteil des Unternehmens?
4743 grundlegende Statistiken
Marktanteil	NT$68.23b
Gewinn(TTM)	-NT$978.89m
Umsatz(TTM)	NT$101.93m

669.4x

Kurs-Umsatz-Verhältnis

-69.7x

Kurs-Gewinn-Verhältnis

Ist 4743 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
4743 Gewinn- und Verlustrechnung (TTM)
Einnahmen	NT$101.93m
Kosten der Einnahmen	NT$52.77m
Bruttogewinn	NT$49.15m
Sonstige Ausgaben	NT$1.03b
Umsatz	-NT$978.89m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-2.05
Bruttomarge	48.22%
Nettogewinnspanne	-960.39%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich 4743 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

4743 Aktienübersicht

Belohnungen

Risikoanalyse

Oneness Biotech Co., Ltd. Wettbewerber

TPEX:6919

NT$82.0b

TWSE:1795

NT$69.7b

TWSE:6472

NT$75.6b

TPEX:6535

NT$54.6b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Price target decreased by 19% to NT$234

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Oneness Biotech Co., Ltd. to Report Q2, 2024 Results on Aug 12, 2024

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Oneness Biotech Co., Ltd. Agrees to Withdraw the 510(K) for Bonvadis Chronic Wound and Resubmit After the Supplementing Animal Study Data

Recent updates

Price target decreased by 19% to NT$234

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Oneness Biotech Co., Ltd. to Report Q2, 2024 Results on Aug 12, 2024

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Oneness Biotech Co., Ltd. Agrees to Withdraw the 510(K) for Bonvadis Chronic Wound and Resubmit After the Supplementing Animal Study Data

US FDA Agrees Oneness Biotech Co., Ltd.'s S.C. Injection Formulation of FB825 to Proceed with Phase 2 Clinical Trial to Treat Moderate-To-Severe Atopic Dermatitis

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Oneness Biotech Co., Ltd. has filed a Follow-on Equity Offering.

Oneness Biotech Co., Ltd., Annual General Meeting, May 21, 2024

Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol Forsubcutaneous Injection Formulation of FB825 in Patientswith Moderate-To-Severe Atopic Dermatitis

Oneness Biotech Co., Ltd. Obtains Import License in Thailand from Thai Food and Drug Administration

Oneness Biotech Co., Ltd. Obtains Import License in Thailand from Thai Food and Drug Administration

Price target decreased by 14% to NT$262

Consensus revenue estimates increase by 158%

Oneness Biotech Co., Ltd. Announces Approval of FESPIXON

New minor risk - Share price stability

New minor risk - Shareholder dilution

Oneness Biotech Co., Ltd. Submits 510(k) Application to the U.S. FDA to Expand the Intended Patient Population and Add Multiple Chronic Wound Indications for Bonvadis

New minor risk - Revenue size

Second quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Profitability

Price target decreased by 10% to NT$274

Oneness Biotech Co., Ltd. Announces Submission of Registration Application for Bonvadis, the Wound Care Topical Cream to the Drug Regulatory Authority of Pakistan (DRAP)

US FDA agrees to proceed with Phase 2 clinical trial for SNS812, a broad-spectrum siRNA for COVID-19 infection, co-developed by Oneness & Microbio (Shanghai)

Oneness Biotech Co., Ltd. Receives Approval from Malaysia NPRA for FESPIXON, the New Drug in Treatment of Diabetic Footulcers

Upcoming dividend of NT$0.098 per share

Oneness Biotech Co., Ltd. Announces Cash Dividend, Payable on July 21, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Oneness Biotech Co., Ltd., Annual General Meeting, Apr 18, 2023

Third quarter 2022 earnings released

Third quarter 2022 earnings released: EPS: NT$0.71 (vs NT$0.46 loss in 3Q 2021)

Microbio (Shanghai) and Oneness Co-Develop Broad-Spectrum siRNA (SNS812) to Treat SARS-CoV-2 Infection, Greenlighted by FDA to Proceed with A Phase I Study

Oneness Biotech Co., Ltd. Submits an IND to US FDA for A Phase Iclinical Trial on the Broad-Spectrum Anti-SARS-CoV-2siRNA (SNS812) Co-Developed with Microbio (Shanghai)

Second quarter 2022 earnings released: EPS: NT$0.87 (vs NT$1.24 loss in 2Q 2021)

Oneness Biotech Co., Ltd. Announces the By-Election of Lin, Yi-Fu as Director

Oneness Biotech Co., Ltd. Announces the By-Election of Lin, Yi-Fu as Director

First quarter 2022 earnings released: EPS: NT$1.01 (vs NT$0.31 in 1Q 2021)

Oneness Biotech Co., Ltd. Announces Food and Drug Administration Philippines Accepts NDA Application of Diabetic Foot Ulcer New Drug, Fespixon

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Oneness Biotech Co., Ltd. Announces The Malaysia National Pharmaceutical Regulatory Agency Accepts NDA Application of the Diabetic Foot Ulcer New Drug, Fespixon

Oneness Biotech Co., Ltd., Annual General Meeting, May 24, 2022

Oneness Biotech Co., Ltd. Announces the Data of Sns812 Were Published by EMBO Molecular Medicine

Oneness Biotech Co., Ltd. Announces the Partial Efficacy Data for the Phase 2a Study of FB825 in the Treatment of Atopic Dermatitis in the U.S

Third quarter 2021 earnings released: NT$0.46 loss per share (vs NT$0.064 profit in 3Q 2020)

Independent Director Kun-Ta Li has left the company

Second quarter 2021 earnings released: NT$1.24 loss per share (vs NT$1.40 profit in 2Q 2020)

Oneness Biotech Co., Ltd. Announces Phase 3 International MRCT Study Results of the Diabetic Foot Ulcer New Drug

First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.54 loss in 1Q 2020)

First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.54 loss in 1Q 2020)

Oneness Notified That FB704A Is Safe to Proceed with the Phase 2 Clinical Trial in Severe Asthma Under US FDA IND

Announcing: Oneness Biotech (GTSM:4743) Stock Soared An Exciting 936% In The Last Three Years

Full year 2020 earnings released: NT$0.68 loss per share (vs NT$1.28 loss in FY 2019)

Oneness Biotech Co., Ltd. Receives the Letter from MOHW Informing that ON101 for DFUs has Obtained the New Drug Approval Andits Drug Certificate Will Be Notified for Receipt

Oneness Biotech Co., Ltd., Annual General Meeting, May 21, 2021

Oneness Submits an IND to US FDA on Phase II Clinical Trial on Severe Asthma of FB704A

Oneness Will Not Proceed with the ON101 Phase3 Clinical Trial (ON101CLCT04) Application with BfArM of Germany Based on Strategic Consideration

Erträge & Einnahmen